APO Research
Talk to an analyst

APO RESEARCH · REPORT

Influenza (Flu) Antiviral Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Influenza (Flu) Antiviral Drugs Industry Research Report 2026

2 January 2026149 pages

Choose your research edition.

Industry ResearchInfluenza (Flu) Antiviral Drugs Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenza (Flu) Antiviral Drugs Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Influenza (Flu) Antiviral Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenza (Flu) Antiviral Drugs Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenza (Flu) Antiviral Drugs Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global Influenza (Flu) Antiviral Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Influenza (Flu) Antiviral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Influenza (Flu) Antiviral Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Influenza (Flu) Antiviral Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Influenza (Flu) Antiviral Drugs include Allergan, Aurobindo Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Bristol-Myers-Squibb, Cipla, F. Hoffmann-La Roche, Gilead Sciences and GlaxoSmithKline (GSK), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Influenza (Flu) Antiviral Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Influenza (Flu) Antiviral Drugs Market by Company

Allergan

Aurobindo Pharma

Boehringer Ingelheim

Bristol-Myers Squibb

Bristol-Myers-Squibb

Cipla

F. Hoffmann-La Roche

Gilead Sciences

GlaxoSmithKline (GSK)

Merck & Co. (MSD)

Novo Nordisk

Teva Pharmaceutical Industries

AstraZeneca

AbbVie

Amgen

Bayer

Pfizer

Eli Lilly

Roche

Mylan

Novartis

Johnson & Johnson

Sanofi

Teva

Takeda

Influenza (Flu) Antiviral Drugs Segment by Type

Neuraminidase Inhibitors

Reverse Transcriptase Inhibitors

Broad-spectrum Antiviral Drugs

Protein Inhibitors

Penetration and Dehulling Inhibitors

DNA Polymerase Inhibitors

Influenza (Flu) Antiviral Drugs Segment by Application

Clinic

Hospital

Household

Others

Influenza (Flu) Antiviral Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza (Flu) Antiviral Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenza (Flu) Antiviral Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza (Flu) Antiviral Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Influenza (Flu) Antiviral Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Influenza (Flu) Antiviral Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Influenza (Flu) Antiviral Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Influenza (Flu) Antiviral Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Influenza (Flu) Antiviral Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Influenza (Flu) Antiviral Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Influenza (Flu) Antiviral Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Influenza (Flu) Antiviral Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Influenza (Flu) Antiviral Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Influenza (Flu) Antiviral Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Influenza (Flu) Antiviral Drugs, Product Type & Application Table 14. Global Influenza (Flu) Antiviral Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Influenza (Flu) Antiviral Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Allergan Company Information Table 19. Allergan Business Overview Table 20. Allergan Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Allergan Influenza (Flu) Antiviral Drugs Product Portfolio Table 22. Allergan Recent Developments Table 23. Aurobindo Pharma Company Information Table 24. Aurobindo Pharma Business Overview Table 25. Aurobindo Pharma Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Aurobindo Pharma Influenza (Flu) Antiviral Drugs Product Portfolio Table 27. Aurobindo Pharma Recent Developments Table 28. Boehringer Ingelheim Company Information Table 29. Boehringer Ingelheim Business Overview Table 30. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Product Portfolio Table 32. Boehringer Ingelheim Recent Developments Table 33. Bristol-Myers Squibb Company Information Table 34. Bristol-Myers Squibb Business Overview Table 35. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Product Portfolio Table 37. Bristol-Myers Squibb Recent Developments Table 38. Bristol-Myers-Squibb Company Information Table 39. Bristol-Myers-Squibb Business Overview Table 40. Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Product Portfolio Table 42. Bristol-Myers-Squibb Recent Developments Table 43. Cipla Company Information Table 44. Cipla Business Overview Table 45. Cipla Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Cipla Influenza (Flu) Antiviral Drugs Product Portfolio Table 47. Cipla Recent Developments Table 48. F. Hoffmann-La Roche Company Information Table 49. F. Hoffmann-La Roche Business Overview Table 50. F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Product Portfolio Table 52. F. Hoffmann-La Roche Recent Developments Table 53. Gilead Sciences Company Information Table 54. Gilead Sciences Business Overview Table 55. Gilead Sciences Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Gilead Sciences Influenza (Flu) Antiviral Drugs Product Portfolio Table 57. Gilead Sciences Recent Developments Table 58. GlaxoSmithKline (GSK) Company Information Table 59. GlaxoSmithKline (GSK) Business Overview Table 60. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Product Portfolio Table 62. GlaxoSmithKline (GSK) Recent Developments Table 63. Merck & Co. (MSD) Company Information Table 64. Merck & Co. (MSD) Business Overview Table 65. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Product Portfolio Table 67. Merck & Co. (MSD) Recent Developments Table 68. Novo Nordisk Company Information Table 69. Novo Nordisk Business Overview Table 70. Novo Nordisk Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Novo Nordisk Influenza (Flu) Antiviral Drugs Product Portfolio Table 72. Novo Nordisk Recent Developments Table 73. Teva Pharmaceutical Industries Company Information Table 74. Teva Pharmaceutical Industries Business Overview Table 75. Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Product Portfolio Table 77. Teva Pharmaceutical Industries Recent Developments Table 78. AstraZeneca Company Information Table 79. AstraZeneca Business Overview Table 80. AstraZeneca Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. AstraZeneca Influenza (Flu) Antiviral Drugs Product Portfolio Table 82. AstraZeneca Recent Developments Table 83. AbbVie Company Information Table 84. AbbVie Business Overview Table 85. AbbVie Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. AbbVie Influenza (Flu) Antiviral Drugs Product Portfolio Table 87. AbbVie Recent Developments Table 88. Amgen Company Information Table 89. Amgen Business Overview Table 90. Amgen Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Amgen Influenza (Flu) Antiviral Drugs Product Portfolio Table 92. Amgen Recent Developments Table 93. Bayer Company Information Table 94. Bayer Business Overview Table 95. Bayer Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Bayer Influenza (Flu) Antiviral Drugs Product Portfolio Table 97. Bayer Recent Developments Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Pfizer Influenza (Flu) Antiviral Drugs Product Portfolio Table 102. Pfizer Recent Developments Table 103. Eli Lilly Company Information Table 104. Eli Lilly Business Overview Table 105. Eli Lilly Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Eli Lilly Influenza (Flu) Antiviral Drugs Product Portfolio Table 107. Eli Lilly Recent Developments Table 108. Roche Company Information Table 109. Roche Business Overview Table 110. Roche Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Roche Influenza (Flu) Antiviral Drugs Product Portfolio Table 112. Roche Recent Developments Table 113. Mylan Company Information Table 114. Mylan Business Overview Table 115. Mylan Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Mylan Influenza (Flu) Antiviral Drugs Product Portfolio Table 117. Mylan Recent Developments Table 118. Novartis Company Information Table 119. Novartis Business Overview Table 120. Novartis Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Novartis Influenza (Flu) Antiviral Drugs Product Portfolio Table 122. Novartis Recent Developments Table 123. Johnson & Johnson Company Information Table 124. Johnson & Johnson Business Overview Table 125. Johnson & Johnson Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Johnson & Johnson Influenza (Flu) Antiviral Drugs Product Portfolio Table 127. Johnson & Johnson Recent Developments Table 128. Sanofi Company Information Table 129. Sanofi Business Overview Table 130. Sanofi Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Sanofi Influenza (Flu) Antiviral Drugs Product Portfolio Table 132. Sanofi Recent Developments Table 133. Teva Company Information Table 134. Teva Business Overview Table 135. Teva Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Teva Influenza (Flu) Antiviral Drugs Product Portfolio Table 137. Teva Recent Developments Table 138. Takeda Company Information Table 139. Takeda Business Overview Table 140. Takeda Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Takeda Influenza (Flu) Antiviral Drugs Product Portfolio Table 142. Takeda Recent Developments Table 143. Global Influenza (Flu) Antiviral Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 144. Global Influenza (Flu) Antiviral Drugs Sales by Region (2021-2026) & (K Units) Table 145. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Region (2021-2026) Table 146. Global Influenza (Flu) Antiviral Drugs Sales by Region (2027-2032) & (K Units) Table 147. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Region (2027-2032) Table 148. Global Influenza (Flu) Antiviral Drugs Revenue by Region (2021-2026) & (US$ Million) Table 149. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Region (2021-2026) Table 150. Global Influenza (Flu) Antiviral Drugs Revenue by Region (2027-2032) & (US$ Million) Table 151. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Region (2027-2032) Table 152. North America Influenza (Flu) Antiviral Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. North America Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units) Table 154. North America Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032) & (K Units) Table 155. North America Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2026) & (US$ Million) Table 156. North America Influenza (Flu) Antiviral Drugs Revenue by Country (2027-2032) & (US$ Million) Table 157. Europe Influenza (Flu) Antiviral Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 158. Europe Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units) Table 159. Europe Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032) & (K Units) Table 160. Europe Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2026) & (US$ Million) Table 161. Europe Influenza (Flu) Antiviral Drugs Revenue by Country (2027-2032) & (US$ Million) Table 162. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 163. Asia Pacific Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units) Table 164. Asia Pacific Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032) & (K Units) Table 165. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2026) & (US$ Million) Table 166. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Country (2027-2032) & (US$ Million) Table 167. South America Influenza (Flu) Antiviral Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 168. South America Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units) Table 169. South America Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032) & (K Units) Table 170. South America Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2026) & (US$ Million) Table 171. South America Influenza (Flu) Antiviral Drugs Revenue by Country (2027-2032) & (US$ Million) Table 172. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 173. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units) Table 174. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032) & (K Units) Table 175. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2026) & (US$ Million) Table 176. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Country (2027-2032) & (US$ Million) Table 177. Global Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (K Units) Table 178. Global Influenza (Flu) Antiviral Drugs Sales by Type (2027-2032) & (K Units) Table 179. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type (2021-2026) Table 180. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type (2027-2032) Table 181. Global Influenza (Flu) Antiviral Drugs Revenue by Type (2021-2026) & (US$ Million) Table 182. Global Influenza (Flu) Antiviral Drugs Revenue by Type (2027-2032) & (US$ Million) Table 183. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2021-2026) Table 184. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2027-2032) Table 185. Global Influenza (Flu) Antiviral Drugs Price by Type (2021-2026) & (US$/Unit) Table 186. Global Influenza (Flu) Antiviral Drugs Price by Type (2027-2032) & (US$/Unit) Table 187. Global Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (K Units) Table 188. Global Influenza (Flu) Antiviral Drugs Sales by Application (2027-2032) & (K Units) Table 189. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application (2021-2026) Table 190. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application (2027-2032) Table 191. Global Influenza (Flu) Antiviral Drugs Revenue by Application (2021-2026) & (US$ Million) Table 192. Global Influenza (Flu) Antiviral Drugs Revenue by Application (2027-2032) & (US$ Million) Table 193. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2021-2026) Table 194. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2027-2032) Table 195. Global Influenza (Flu) Antiviral Drugs Price by Application (2021-2026) & (US$/Unit) Table 196. Global Influenza (Flu) Antiviral Drugs Price by Application (2027-2032) & (US$/Unit) Table 197. Key Raw Materials Table 198. Raw Materials Key Suppliers Table 199. Influenza (Flu) Antiviral Drugs Distributors List Table 200. Influenza (Flu) Antiviral Drugs Customers List Table 201. Influenza (Flu) Antiviral Drugs Industry Trends Table 202. Influenza (Flu) Antiviral Drugs Industry Drivers Table 203. Influenza (Flu) Antiviral Drugs Industry Restraints Table 204. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Influenza (Flu) Antiviral Drugs Product Image Figure 5. Global Influenza (Flu) Antiviral Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Influenza (Flu) Antiviral Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Influenza (Flu) Antiviral Drugs Sales (2021-2032) & (K Units) Figure 8. Global Influenza (Flu) Antiviral Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. Neuraminidase Inhibitors Product Image Figure 10. Reverse Transcriptase Inhibitors Product Image Figure 11. Broad-spectrum Antiviral Drugs Product Image Figure 12. Protein Inhibitors Product Image Figure 13. Penetration and Dehulling Inhibitors Product Image Figure 14. DNA Polymerase Inhibitors Product Image Figure 15. Clinic Product Image Figure 16. Hospital Product Image Figure 17. Household Product Image Figure 18. Others Product Image Figure 19. Global Influenza (Flu) Antiviral Drugs Revenue Share by Manufacturers in 2025 Figure 20. Global Manufacturers of Influenza (Flu) Antiviral Drugs, Manufacturing Sites & Headquarters Figure 21. Global Top 5 and 10 Influenza (Flu) Antiviral Drugs Players Market Share by Revenue in 2025 Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Influenza (Flu) Antiviral Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 24. Global Influenza (Flu) Antiviral Drugs Sales by Region in 2025 Figure 25. Global Influenza (Flu) Antiviral Drugs Revenue by Region in 2025 Figure 26. North America Influenza (Flu) Antiviral Drugs Market Size by Country in 2025 Figure 27. North America Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2032) Figure 28. North America Influenza (Flu) Antiviral Drugs Revenue Market Share by Country (2021-2032) Figure 29. United States Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Canada Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe Influenza (Flu) Antiviral Drugs Market Size by Country in 2025 Figure 32. Europe Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2032) Figure 33. Europe Influenza (Flu) Antiviral Drugs Revenue Market Share by Country (2021-2032) Figure 34. Germany Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Nordic Countries Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Influenza (Flu) Antiviral Drugs Market Size by Country in 2025 Figure 41. Asia Pacific Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Influenza (Flu) Antiviral Drugs Revenue Market Share by Country (2021-2032) Figure 43. China Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. China Taiwan Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Influenza (Flu) Antiviral Drugs Market Size by Country in 2025 Figure 52. South America Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2032) Figure 53. South America Influenza (Flu) Antiviral Drugs Revenue Market Share by Country (2021-2032) Figure 54. Mexico Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Brazil Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Argentina Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Colombia Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Middle East and Africa Influenza (Flu) Antiviral Drugs Market Size by Country in 2025 Figure 59. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2032) Figure 60. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue Market Share by Country (2021-2032) Figure 61. Turkey Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Saudi Arabia Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. UAE Influenza (Flu) Antiviral Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type (2021-2032) Figure 65. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2021-2032) Figure 66. Global Influenza (Flu) Antiviral Drugs Price (US$/Unit) by Type (2021-2032) Figure 67. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application (2021-2032) Figure 68. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2021-2032) Figure 69. Global Influenza (Flu) Antiviral Drugs Price (US$/Unit) by Application (2021-2032) Figure 70. Influenza (Flu) Antiviral Drugs Value Chain Figure 71. Influenza (Flu) Antiviral Drugs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Influenza (Flu) Antiviral Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Neuraminidase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Broad-spectrum Antiviral Drugs
  • Protein Inhibitors
  • Penetration and Dehulling Inhibitors
  • DNA Polymerase Inhibitors
Applications
  • Clinic
  • Hospital
  • Household
  • Others
Companies covered
  • Allergan
  • Aurobindo Pharma
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Bristol-Myers-Squibb
  • Cipla
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Merck & Co. (MSD)
  • Novo Nordisk
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • AbbVie
  • Amgen
  • Bayer
  • Pfizer
  • Eli Lilly
  • Roche
  • Mylan
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Teva
  • Takeda

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Influenza (Flu) Antiviral Drugs Market Size (2021-2032)
  4. 2.2.2 Global Influenza (Flu) Antiviral Drugs Sales (2021-2032)
  5. 2.2.3 Global Influenza (Flu) Antiviral Drugs Market Average Price (2021-2032)
  6. 2.3 Influenza (Flu) Antiviral Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Neuraminidase Inhibitors
  9. 2.3.3 Reverse Transcriptase Inhibitors
  10. 2.3.4 Broad-spectrum Antiviral Drugs
  11. 2.3.5 Protein Inhibitors
  12. 2.3.6 Penetration and Dehulling Inhibitors
  13. 2.3.7 DNA Polymerase Inhibitors
  14. 2.4 Influenza (Flu) Antiviral Drugs by Application
  15. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  16. 2.4.2 Clinic
  17. 2.4.3 Hospital
  18. 2.4.4 Household
  19. 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Influenza (Flu) Antiviral Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Influenza (Flu) Antiviral Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Influenza (Flu) Antiviral Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Influenza (Flu) Antiviral Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Influenza (Flu) Antiviral Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Influenza (Flu) Antiviral Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Influenza (Flu) Antiviral Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Influenza (Flu) Antiviral Drugs, Established Date
  9. 3.9 Global Influenza (Flu) Antiviral Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Allergan
  2. 4.1.1 Allergan Company Information
  3. 4.1.2 Allergan Business Overview
  4. 4.1.3 Allergan Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Allergan Influenza (Flu) Antiviral Drugs Product Portfolio
  6. 4.1.5 Allergan Recent Developments
  7. 4.2 Aurobindo Pharma
  8. 4.2.1 Aurobindo Pharma Company Information
  9. 4.2.2 Aurobindo Pharma Business Overview
  10. 4.2.3 Aurobindo Pharma Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Aurobindo Pharma Influenza (Flu) Antiviral Drugs Product Portfolio
  12. 4.2.5 Aurobindo Pharma Recent Developments
  13. 4.3 Boehringer Ingelheim
  14. 4.3.1 Boehringer Ingelheim Company Information
  15. 4.3.2 Boehringer Ingelheim Business Overview
  16. 4.3.3 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Product Portfolio
  18. 4.3.5 Boehringer Ingelheim Recent Developments
  19. 4.4 Bristol-Myers Squibb
  20. 4.4.1 Bristol-Myers Squibb Company Information
  21. 4.4.2 Bristol-Myers Squibb Business Overview
  22. 4.4.3 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Product Portfolio
  24. 4.4.5 Bristol-Myers Squibb Recent Developments
  25. 4.5 Bristol-Myers-Squibb
  26. 4.5.1 Bristol-Myers-Squibb Company Information
  27. 4.5.2 Bristol-Myers-Squibb Business Overview
  28. 4.5.3 Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Product Portfolio
  30. 4.5.5 Bristol-Myers-Squibb Recent Developments
  31. 4.6 Cipla
  32. 4.6.1 Cipla Company Information
  33. 4.6.2 Cipla Business Overview
  34. 4.6.3 Cipla Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Cipla Influenza (Flu) Antiviral Drugs Product Portfolio
  36. 4.6.5 Cipla Recent Developments
  37. 4.7 F. Hoffmann-La Roche
  38. 4.7.1 F. Hoffmann-La Roche Company Information
  39. 4.7.2 F. Hoffmann-La Roche Business Overview
  40. 4.7.3 F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Product Portfolio
  42. 4.7.5 F. Hoffmann-La Roche Recent Developments
  43. 4.8 Gilead Sciences
  44. 4.8.1 Gilead Sciences Company Information
  45. 4.8.2 Gilead Sciences Business Overview
  46. 4.8.3 Gilead Sciences Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Gilead Sciences Influenza (Flu) Antiviral Drugs Product Portfolio
  48. 4.8.5 Gilead Sciences Recent Developments
  49. 4.9 GlaxoSmithKline (GSK)
  50. 4.9.1 GlaxoSmithKline (GSK) Company Information
  51. 4.9.2 GlaxoSmithKline (GSK) Business Overview
  52. 4.9.3 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Product Portfolio
  54. 4.9.5 GlaxoSmithKline (GSK) Recent Developments
  55. 4.10 Merck & Co. (MSD)
  56. 4.10.1 Merck & Co. (MSD) Company Information
  57. 4.10.2 Merck & Co. (MSD) Business Overview
  58. 4.10.3 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Product Portfolio
  60. 4.10.5 Merck & Co. (MSD) Recent Developments
  61. 4.11 Novo Nordisk
  62. 4.11.1 Novo Nordisk Company Information
  63. 4.11.2 Novo Nordisk Business Overview
  64. 4.11.3 Novo Nordisk Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Novo Nordisk Influenza (Flu) Antiviral Drugs Product Portfolio
  66. 4.11.5 Novo Nordisk Recent Developments
  67. 4.12 Teva Pharmaceutical Industries
  68. 4.12.1 Teva Pharmaceutical Industries Company Information
  69. 4.12.2 Teva Pharmaceutical Industries Business Overview
  70. 4.12.3 Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Product Portfolio
  72. 4.12.5 Teva Pharmaceutical Industries Recent Developments
  73. 4.13 AstraZeneca
  74. 4.13.1 AstraZeneca Company Information
  75. 4.13.2 AstraZeneca Business Overview
  76. 4.13.3 AstraZeneca Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 AstraZeneca Influenza (Flu) Antiviral Drugs Product Portfolio
  78. 4.13.5 AstraZeneca Recent Developments
  79. 4.14 AbbVie
  80. 4.14.1 AbbVie Company Information
  81. 4.14.2 AbbVie Business Overview
  82. 4.14.3 AbbVie Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 AbbVie Influenza (Flu) Antiviral Drugs Product Portfolio
  84. 4.14.5 AbbVie Recent Developments
  85. 4.15 Amgen
  86. 4.15.1 Amgen Company Information
  87. 4.15.2 Amgen Business Overview
  88. 4.15.3 Amgen Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Amgen Influenza (Flu) Antiviral Drugs Product Portfolio
  90. 4.15.5 Amgen Recent Developments
  91. 4.16 Bayer
  92. 4.16.1 Bayer Company Information
  93. 4.16.2 Bayer Business Overview
  94. 4.16.3 Bayer Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Bayer Influenza (Flu) Antiviral Drugs Product Portfolio
  96. 4.16.5 Bayer Recent Developments
  97. 4.17 Pfizer
  98. 4.17.1 Pfizer Company Information
  99. 4.17.2 Pfizer Business Overview
  100. 4.17.3 Pfizer Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Pfizer Influenza (Flu) Antiviral Drugs Product Portfolio
  102. 4.17.5 Pfizer Recent Developments
  103. 4.18 Eli Lilly
  104. 4.18.1 Eli Lilly Company Information
  105. 4.18.2 Eli Lilly Business Overview
  106. 4.18.3 Eli Lilly Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Eli Lilly Influenza (Flu) Antiviral Drugs Product Portfolio
  108. 4.18.5 Eli Lilly Recent Developments
  109. 4.19 Roche
  110. 4.19.1 Roche Company Information
  111. 4.19.2 Roche Business Overview
  112. 4.19.3 Roche Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Roche Influenza (Flu) Antiviral Drugs Product Portfolio
  114. 4.19.5 Roche Recent Developments
  115. 4.20 Mylan
  116. 4.20.1 Mylan Company Information
  117. 4.20.2 Mylan Business Overview
  118. 4.20.3 Mylan Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Mylan Influenza (Flu) Antiviral Drugs Product Portfolio
  120. 4.20.5 Mylan Recent Developments
  121. 4.21 Novartis
  122. 4.21.1 Novartis Company Information
  123. 4.21.2 Novartis Business Overview
  124. 4.21.3 Novartis Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Novartis Influenza (Flu) Antiviral Drugs Product Portfolio
  126. 4.21.5 Novartis Recent Developments
  127. 4.22 Johnson & Johnson
  128. 4.22.1 Johnson & Johnson Company Information
  129. 4.22.2 Johnson & Johnson Business Overview
  130. 4.22.3 Johnson & Johnson Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Johnson & Johnson Influenza (Flu) Antiviral Drugs Product Portfolio
  132. 4.22.5 Johnson & Johnson Recent Developments
  133. 4.23 Sanofi
  134. 4.23.1 Sanofi Company Information
  135. 4.23.2 Sanofi Business Overview
  136. 4.23.3 Sanofi Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 Sanofi Influenza (Flu) Antiviral Drugs Product Portfolio
  138. 4.23.5 Sanofi Recent Developments
  139. 4.24 Teva
  140. 4.24.1 Teva Company Information
  141. 4.24.2 Teva Business Overview
  142. 4.24.3 Teva Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  143. 4.24.4 Teva Influenza (Flu) Antiviral Drugs Product Portfolio
  144. 4.24.5 Teva Recent Developments
  145. 4.25 Takeda
  146. 4.25.1 Takeda Company Information
  147. 4.25.2 Takeda Business Overview
  148. 4.25.3 Takeda Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  149. 4.25.4 Takeda Influenza (Flu) Antiviral Drugs Product Portfolio
  150. 4.25.5 Takeda Recent Developments
5 Global Influenza (Flu) Antiviral Drugs Market Scenario by Region
  1. 5.1 Global Influenza (Flu) Antiviral Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Influenza (Flu) Antiviral Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Influenza (Flu) Antiviral Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Influenza (Flu) Antiviral Drugs Sales by Region: 2027-2032
  5. 5.3 Global Influenza (Flu) Antiviral Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Influenza (Flu) Antiviral Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Influenza (Flu) Antiviral Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Influenza (Flu) Antiviral Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Influenza (Flu) Antiviral Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Influenza (Flu) Antiviral Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Influenza (Flu) Antiviral Drugs Market Facts & Figures by Country
  15. 5.5.1 Europe Influenza (Flu) Antiviral Drugs Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Influenza (Flu) Antiviral Drugs Sales by Country (2021-2032)
  17. 5.5.3 Europe Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.5.9 Nordic Countries
  24. 5.6 Asia Pacific Influenza (Flu) Antiviral Drugs Market Facts & Figures by Country
  25. 5.6.1 Asia Pacific Influenza (Flu) Antiviral Drugs Market Size by Country: 2021 VS 2025 VS 2032
  26. 5.6.2 Asia Pacific Influenza (Flu) Antiviral Drugs Sales by Country (2021-2032)
  27. 5.6.3 Asia Pacific Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2032)
  28. 5.6.4 China
  29. 5.6.5 Japan
  30. 5.6.6 South Korea
  31. 5.6.7 India
  32. 5.6.8 Australia
  33. 5.6.9 China Taiwan
  34. 5.6.10 Southeast Asia
  35. 5.7 South America Influenza (Flu) Antiviral Drugs Market Facts & Figures by Country
  36. 5.7.1 South America Influenza (Flu) Antiviral Drugs Market Size by Country: 2021 VS 2025 VS 2032
  37. 5.7.2 South America Influenza (Flu) Antiviral Drugs Sales by Country (2021-2032)
  38. 5.7.3 South America Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2032)
  39. 5.7.4 Mexico
  40. 5.7.5 Brazil
  41. 5.7.6 Argentina
  42. 5.7.7 Colombia
  43. 5.8 Middle East and Africa Influenza (Flu) Antiviral Drugs Market Facts & Figures by Country
  44. 5.8.1 Middle East and Africa Influenza (Flu) Antiviral Drugs Market Size by Country: 2021 VS 2025 VS 2032
  45. 5.8.2 Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Country (2021-2032)
  46. 5.8.3 Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue by Country (2021-2032)
  47. 5.8.4 Turkey
  48. 5.8.5 Saudi Arabia
  49. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Influenza (Flu) Antiviral Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Influenza (Flu) Antiviral Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Influenza (Flu) Antiviral Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Influenza (Flu) Antiviral Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Influenza (Flu) Antiviral Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Influenza (Flu) Antiviral Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Influenza (Flu) Antiviral Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Influenza (Flu) Antiviral Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Influenza (Flu) Antiviral Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Influenza (Flu) Antiviral Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Influenza (Flu) Antiviral Drugs Value Chain Analysis
  2. 8.1.1 Influenza (Flu) Antiviral Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Influenza (Flu) Antiviral Drugs Production Mode & Process
  5. 8.2 Influenza (Flu) Antiviral Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Influenza (Flu) Antiviral Drugs Distributors
  8. 8.2.3 Influenza (Flu) Antiviral Drugs Customers
9 Global Influenza (Flu) Antiviral Drugs Analyzing Market Dynamics
  1. 9.1 Influenza (Flu) Antiviral Drugs Industry Trends
  2. 9.2 Influenza (Flu) Antiviral Drugs Industry Drivers
  3. 9.3 Influenza (Flu) Antiviral Drugs Industry Opportunities and Challenges
  4. 9.4 Influenza (Flu) Antiviral Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst